HLB Therapeutics Co.,Ltd. Logo

HLB Therapeutics Co.,Ltd.

Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.

115450 | KO

Overview

Corporate Details

ISIN(s):
KR7115450009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 정자일로 248, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's core focus is on its clinical pipeline, which includes RGN-259, a therapeutic candidate for ophthalmic conditions such as Neurotrophic Keratopathy and Dry Eye Disease, and OKN-007 for treating Glioblastoma Multiforme. In addition to its primary research and development activities, the company has diversified business areas that include vaccine distribution and cold chain logistics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-28 00:00
Share Issue/Capital Change
전환가액의조정
Korean 10.6 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 137.3 KB
2025-08-21 00:00
Share Issue/Capital Change
전환가액의조정
Korean 11.8 KB
2025-08-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 137.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 136.8 KB
2025-07-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 141.7 KB
2025-07-03 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-07-01 00:00
Share Issue/Capital Change
전환가액의조정
Korean 13.1 KB
2025-06-20 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 73.7 KB
2025-05-28 00:00
Share Issue/Capital Change
전환가액의조정 (제18회차)
Korean 10.2 KB
2025-05-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-05-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 119.0 KB
2025-05-21 00:00
Share Issue/Capital Change
전환가액의조정 (제17회차)
Korean 11.3 KB

Automate Your Workflow. Get a real-time feed of all HLB Therapeutics Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Therapeutics Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Therapeutics Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.